Loris Knümann

Research Interest

 

Publications

Ge, X.; Willems, S.; Melfi, F.; Mukhopadhyay, T.; Morstein, J.; Artzy, J.; Knümann, L.; Sbriccoli, G.; Pabel, J.; Marschner, J.A.; Trauner, D.; Merk, D. Bidirectional optical control of osteogenesis with a light activated vitamin D mimetic. Angew. Chem. Int. Ed., 2026 DOI

Hank, E.; Busch, R.; López-García, Ú.; Kasch, T.; Knümann, L.; Morozov, V.; Höfner, G.; Marschner, J.A.; Merk, D. An activator of tailless’ repressor function stimulates anti-neurodegenerative gene expression. J. Med. Chem., 2026 DOI

Hank, E.; Knümann, L.; López-García, U.; Kardanov, A.; Morozov, V.; Höfner, G.; Merk, D. Systematic optimization of fragment TLX ligands towards agonism and inverse agonism. J. Med. Chem., 2026 DOI

Lewandowski, M.; Carmina, M.; Knümann, L.; Sai, M.; Willems, S.; Kasch, T.; Pollinger, J.; Knapp, S.; Marschner, J. A.; Chaikuad, A.; Merk, D. Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties. J. Med. Chem., 2024, 67, 2152–2164. DOI

Adouvi, G.; Nawa, F.; Ballarotto, M.; Rüger, L. A.; Knümann, L.; Kasch, T.; Arifi, S.; Schubert-Zsilavecz, M.; Willems, S.; Marschner, J. A.; Pabel, J.; Merk, D. Structural Fusion of Natural and Synthetic Ligand Features Boosts RXR Agonist Potency. J. Med. Chem., 2023, 66, 16762–16771. DOI